Corporate information

Company Name

M Bio Technology Inc.

 

Location

  • Headquarters:

     2-3-103 Fukasawa, Setagaya-ku, Tokyo 158-0081

  • Research Institute:

     Chiba University Inohana Innovation Plaza #206

     1-8-15 Inohana, Chuo-ku, Chiba-shi, Chiba 260-0856           

     

Established

January 5, 2005

 

Main Business Activities

  • Development of diagnostics, therapeutics and vaccines for mycoplasma infections

  • Development of various preventive and non-diseased medical treatments for mycoplasma infections

 

Capital

231,210,000 yen (as of the end of March 2021)

 

​Management Team

  • Kazuhiro Matsuda, President and CEO

  • Sachie Matsuda, Vice President and Representative Director

  • Makoto Nakamura, Managing Director

  • Hiroki Okimoto, Director

  • Kentarou Tsutsumi, Audit & Supervisory Board Member

Competitive fund management regulations (Japanese version only)

Basic policy on operation and management of competitive funds and research misconduct
(Japanese version only)

Financial results summary (in preparation)

History

January 2005

April 2006

Established M Bio Technology Inc.

Started joint research project "Diagnosis of rheumatic diseases targeting mycoplasma-specific lipid synthase-Research and development of therapeutic system" with Bioinformatics Research Center, Industrial Technology Research Institute

July 2019

Support for overseas expansion by JETRO's "New Export Power Consortium" experts. Since it was adopted as a target drug discovery venture, we are focusing on expanding our global presence. (Adopted in 2020 and 2021)

November 2018

Received the New Value Creation Award at the New Value Creation Exhibition 2018 sponsored by the Organization for Small & Medium Enterprises and Regional Innovation, Japan.

January 2018

Concluded a memorandum of understanding with a major domestic pharmaceutical company for joint research and development of therapeutic agents for rare neurological diseases caused by mycoplasma infection.

 

April 2012

In partnership with a major testing company, SRL, Inc., we started self-financed medical care for mycoplasma infections using MID Prism®.

April 2012

Established Mycoplasma Infectious Diseases Research Center at Chiba Inohana Innovation Plaza, Organization for Small & Medium Enterprises and Regional Innovation.

 

June 2010

Patent application for vaccine for mycoplasma infectious disease as part of the project of National Institute of Advanced Industrial Science and Technology

July 2006

New Energy and Industrial Technology Development Organization (NEDO) Subsidy Adopted: Industrial Technology Practical Development Expense Subsidy R & D Venture Technology Development Subsidy "Development of Rapid Analysis System for Lipid Antigens from Patient Serum by Mass Spectrometry" (Research representative Kazuhiro Matsuda) started

June 2007

Mycoplasma glycolipid antigenic substance patent application

January 2009

Ministry of Economy, Trade and Industry's Venture Support Appointment System Adopted: National Institute of Advanced Industrial Science and Technology Biomedical Information Research Center Task Force Project "Technology Development of Mycoplasma Infectious Disease Vaccine" (Technology Development Team Leader, Kazuhiro Matsuda)

August 2020

Started joint research with Yamaguchi University Department of Medical and Neurology, "Fact-finding survey of mycoplasma infections using stored serum from CIDP patients, and retrospective research"

May 2006

The Intractable Disease Overcome Research Project (Study Group for Investigation of Microbial Causes of Specific Diseases) was adopted as a subsidy for scientific research by the Ministry of Health, Labor and Welfare. Study on development of rheumatic disease model using fungus-administered rabbits and study on the involvement of mycoplasma in autoantibody production in antiphospholipid antibody syndrome ”